drugset
drugset / Trial / NCT06375161

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

NCT06375161 ↗

Phase 0 Recruiting 12 enrolled Shanghai Tongji Hospital, Tongji University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment. In this study phase, a traditional "3+3" trial design is employed for dose escalation.

Timeline

Start
2023-12-11
Primary completion
2025-12-10
Completion
2039-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD19 CAR-T cells Cell therapy 100000 cells/kg Intravenous
Subject anti-CD19 CAR-T cells Cell therapy 300000 cells/kg Intravenous
Subject anti-CD19 CAR-T cells Cell therapy 1e+06 cells/kg Intravenous

Indications

B-cell neoplasm